Shares of Eli Lilly (LLY) got a nice boost on Wednesday. The reason? The Food and Drug Administration gave its blessing to a new oral weight-loss drug called Foundayo. This is a pretty big deal—it's Lilly's second FDA-approved obesity treatment, and it solidifies the company's spot in the red-hot market for GLP-1 drugs and their cousins.
So, what does this pill do? In the ATTAIN-1 trial, adults on the highest dose lost an average of 27 pounds, which works out to about 12.4% of their body weight. It's a once-daily pill, and Lilly plans to sell it through its LillyDirect platform. The price tag: $25 per month for patients with commercial insurance, and $149 per month for those paying out of pocket. The company also noted that eligible Medicare Part D patients could get it for $50 a month starting in July 2026. One important safety note: Lilly says Foundayo shouldn't be used alongside other GLP-1 receptor agonists.
The approval came on a day when the broader market was feeling pretty good—the S&P 500 was up 1.2% and healthcare stocks gained 1.16%. But Lilly shares did even better, which tells you investors liked what they heard. The company plans to launch Foundayo in the U.S. first, then expand to more than 40 countries.
Checking the Charts
Let's look under the hood. The stock is currently trading 1.3% above its 20-day simple moving average, which suggests some short-term strength. But it's also 5.4% below its 100-day moving average, so the picture is a bit mixed. Over the past year, shares are up a solid 20.07%, and they're sitting closer to their 52-week highs than their lows.
The Relative Strength Index (RSI) is at 42.07, which is considered neutral—not overbought, not oversold. Meanwhile, the MACD is sitting at -33.0436, which is below its signal line. That typically indicates some bearish pressure. Put it together, and you've got mixed momentum signals.
- Key Resistance: $1,114.00
- Key Support: $965.50
How's the Sector Doing?
Eli Lilly is currently outperforming the healthcare sector, which is ranked 4th out of 11 sectors and gained 1.16% today. That's notable because over the past 30 days, the healthcare sector has actually declined 6.44%. So Lilly's move is a bright spot in what's been a tough environment for health stocks.
The Foundayo approval is strategically important. It expands Lilly's portfolio in the obesity treatment market at a time when obesity rates are rising globally. This move helps the company compete more effectively in a landscape that's getting increasingly crowded.
What Are the Analysts Saying?
Eli Lilly is scheduled to report earnings on April 30, 2026. Here's what the Street is expecting:
- EPS Estimate: $7.36 (up from $3.34)
- Revenue Estimate: $17.62 billion (up from $12.73 billion)
- Valuation: P/E of 40.1x (that's a premium valuation)
The analyst consensus is a Buy rating with an average price target of $1,177.40. But not everyone is on the same page. Recent moves include:
- Guggenheim: Buy rating, but lowered their target to $1,163.00 (March 30)
- HSBC: Downgraded to Reduce and lowered their target to $850.00 (March 17)
- RBC Capital: Initiated coverage with an Outperform rating and a $1,250.00 target (February 25)
ETF Exposure: Why It Matters
Eli Lilly is a major holding in several exchange-traded funds. That means when money flows into or out of these ETFs, the managers have to buy or sell Lilly stock to match the fund's target weight. Here are some of the big ones:
The significance here is pretty straightforward: because LLY carries such heavy weight in these funds, any significant inflows or outflows will likely force automatic buying or selling of the stock. It's a mechanical relationship that can add extra volatility.
Price Action
So how did the stock actually trade? Eli Lilly shares were up 4.82% at $964.06 at the time of publication on Wednesday, according to market data.
